ClinicalTrials.gg
RecruitingNCT07718802OASISUpdated Oct 15, 2026

Observational Approach Versus Surgical Intervention for Stones

An interventional study of Surgery and Observation in Nephrolithiasis and Kidney Stone, sponsored by Children's Hospital of Philadelphia. Recruiting at 4 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Primary conditionKidney CalculiRegistry: NephrolithiasisReclassifiedWhy we changed it
Registry
Nephrolithiasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Calculi
Why
  1. The study's listed conditions name Kidney Calculi, a narrower term within Nephrolithiasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Children's Hospital of Philadelphia · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 15, 20263 sites added1 site removedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
1,658
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Study summary

The aims of the Observational Approach versus Surgical Intervention for Asymptomatic Stone (OASIS) trial are: 1) to determine whether observation compared to upfront surgery results in less healthcare-related life disruption due to kidney stones among children and adults with asymptomatic kidney stones; 2) to identify the groups benefiting the most from each strategy; and 3) to determine the preferences and values informing the choice between observation and upfront surgery.

Read the detailed description

A critical barrier to improving the health of the nearly 40 million Americans with kidney stone disease is the weak evidence base supporting the management of individuals with asymptomatic kidney stones. The proposed Observational Approach versus Surgical Intervention for Asymptomatic Stone (OASIS) randomized clinical trial answers the research question of whether observation or upfront surgery results in less life disruption from asymptomatic kidney stones for children and adults. The management options for patients with asymptomatic stones are 1) observation or 2) upfront surgical treatment, both of which are considered safe, part of usual care, widely accessible, and covered by insurance.

OASIS responds to the charge for well-designed Randomized Controlled Trials (RCT) from the Agency for Healthcare Research and Quality (AHRQ) systematic review on kidney stone disease management and ensures patient centeredness by examining outcomes that patients have identified as meaningful.

Intervention

Randomization to either:

  1. Observation is the surveillance of asymptomatic stones with periodic CT, ultrasound, or x-ray, and clinic visits.
  2. Upfront surgery is the planned removal of asymptomatic stones and includes ureteroscopy (URS) and shockwave lithotripsy (SWL), which are routinely used in standard clinical care.

Observational Cohort (Non-Randomized Cohort):

Up to 300 eligible subjects who are willing to consent to data collection but refuse randomization will be enrolled and followed for two years.

Study Design OASIS is a pragmatic randomized controlled superiority trial conducted at approximately 30 sites that participate in Patient Centered Outcomes Research Network (PCORnet). The trial will include an additional observational cohort for eligible subjects who decline randomization.

02

Conditions studied

  • Nephrolithiasis
  • Kidney Stone

Browse trials for

Keywords

  • kidney stones
  • kidney
  • nephrolithiasis
  • Comparative Effectiveness
  • Patient Reported Outcomes
03

In context

Kidney Calculi Reclassified

509 studies on the registry are indexed under Kidney Calculi; 146 are open to participants now.

This study's planned enrollment of 1,658 is above the median of 86 across 391 interventional studies indexed under Kidney Calculi.

Browse Kidney Calculi studies →

Lead sponsor

Children's Hospital of Philadelphia is the lead sponsor of 489 studies on the registry; 90 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 22 (79%) have results posted.

Compared within Kidney Calculi, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nephrolithiasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals age 6 or older
  2. Diagnosis of kidney stone disease (nephrolithiasis)
  3. Asymptomatic, non-obstructive kidney stones measuring 4 to 10 mm (inclusive)

    • Asymptomatic is defined as the absence of abdominal pain, flank pain, gross hematuria, and nausea and/or vomiting in the last 3 months that in the judgement of the site PI could be attributable to kidney stones.
    • Non-obstructive is defined as a stone in a renal calyx or stones in multiple renal calyces on CT, ultrasound, and/or x-ray obtained within 6 months of screening.
  4. and if appropriate, child assent.
  5. Willingness to be randomized to surgery or observation Note: subjects otherwise eligible who decline randomization may be enrolled in a parallel observational cohort.
  6. Fluent in English or Spanish
  7. Willingness to be audio- and/or video- recorded during interviews

Exclusion criteria

Exclusion Criteria:

  1. Untreated hydronephrosis or caliectasis
  2. Pain (e.g., renal colic, abdominal pain) or gross hematuria attributed to kidney stones.
  3. Recurrent symptomatic urinary tract infections (≥3 in 12 months or ≥2 in 6 months). A symptomatic urinary tract infection is defined as having at least one bladder or voiding symptom (e.g., frequency, urgency, dysuria) with bacteriuria (≥105 colony forming units/mL of no more than 2 urinary tract pathogens).
  4. Stone in the renal pelvis, ureter, bladder or urethra
  5. Pregnant females
  6. Solitary kidney, transplant kidney, urinary diversion, medullary sponge kidney
  7. Anatomic abnormality of the kidney (e.g., horseshoe kidney)
  8. Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,658 participants (estimated)

Study arms

  • Active comparator
    Non-Randomized (Observational)

    Procedure: Surgery · Other: Observation

  • Active comparator
    Randomized

    Procedure: Surgery · Other: Observation

Interventions

  • ProcedureSurgery

    Upfront surgery is the planned removal of asymptomatic stones and includes ureteroscopy and shockwave lithotripsy, which are routinely used in standard clinical care.

  • OtherObservation

    Observation is the surveillance of asymptomatic stones with periodic CT, ultrasound, or x-ray, and clinic visits.

06

What researchers measure

Primary outcomes

  1. Healthcare-related life disruption

    Composite of: Stone-specific emergency department (ED)/urgent care visits, stone-specific hospitalizations and surgery for stones for new symptoms (Shockwave Lithotripsy (SWL) and Ureteroscopy (URS)) as reported via Patient Centered Outcomes Research Network (PCORnet) Common Data Model (CDM) query and participant self-report on REDCap.

    Time frame: Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.

Secondary outcomes

  1. Patient reported physical and emotional health (Pain Interference)

    Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference (PI) is a standardized, self-reported assessment tool developed by the National Institutes of Health (NIH). It measures how much pain hinders a person's physical, mental, social, and recreational activities, as well as their sleep and enjoyment of life. It uses a standardized T-score (average is 50; standard deviation is 10) to reflect the level of disruption. Higher numbers mean more pain interference (pain is having a greater negative impact on your daily life, making it harder to participate in work, social, and physical activities). The study team is using the validated versions for adults (18 years and older at time of consent), children (ages 8-17 years at time of consent), and parent-proxy versions for caregivers of children ages (6-7 years at time of consent). This information will be captured via patient report in REDCap.

    Time frame: Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.

  2. Patient reported physical and emotional health (Anxiety)

    Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety is a standardized, self-reported assessment tool developed by the National Institutes of Health (NIH). It measures the severity of fear, worry, dread, hyperarousal, and physical stress symptoms over the past seven days on a 5-point scale (ranging from never to always). Raw scores are converted into a standardized T-score with an average of 50 and a standard deviation of 10. A higher T-score indicates a higher severity of anxiety. The study team is using validated versions for adults (18 years and older at time of consent), children (ages 8-17 years at time of consent), and parent-proxy versions for caregivers of children ages (6-7 years at time of consent). This information will be captured via patient report in REDCap.

    Time frame: Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.

  3. Patient reported physical and emotional health (Stone Quality of Life)

    The Wisconsin Stone Quality of Life questionnaire (WISQOL) is a disease-specific health-related quality of life (HRQOL) instrument designed to assess the impact on patients of stones in the urinary tract. Each item is scored on a 5-point Likert scale, yielding a total raw score of 28 to 140. Higher scores reflect a better health-related quality of life. Raw scores are typically converted to a standardized 0-100 scale. This information will be captured via patient report on REDCap.

    Time frame: Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.

  4. Stone passage

    Patient Reported Survey: Number of self-reported stone passages (A kidney stone episode is passing a stone that caused pain or other bothersome symptoms or having surgery to remove a stone.) This information will be captured via patient report on REDCap.

    Time frame: Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months. Reporting total after 2 years.

  5. Lost productivity (Missed School)

    Patient Reported Survey: Number of days the patient (for patients under 18 years old at time of consent) missed school due to kidney stones or kidney stone-related care (0 days, 1-2 days, 3-5 days, 6-10 days, more than 10 days) in the last 3 months. This information will be captured via patient report in REDCap.

    Time frame: Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.

  6. Lost productivity (Caregiver Missed Work)

    Patient Reported Survey: Number of days the patient's caregiver(s) (for patients \<18 years old at time of consent) missed work due to kidney stones or kidney stone-related care (0 days, 1-2 days, 3-5 days, 6-10 days, more than 10 days) in the last 3 months. This information will be captured via patient report on REDCap.

    Time frame: Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.

  7. Lost productivity (Patient Missed Work)

    Patient Reported Survey: Number of days the patient missed work (for patients 18 years and older at time of consent) due to kidney stones or kidney stone-related care (0 days, 1-2 days, 3-5 days, 6-10 days, More than 10 days) in the last 3 months. This information will be captured via patient report in REDCap.

    Time frame: Every 3 months (+/- 14 days) from date of consent (observational cohort) or randomization (randomized cohort) until 24 months.

07

Study locations

2 of 4 sites recruiting
  • University of California, Irvine
    Irvine, California 92612, United States
    Recruiting
    • Ryan Hsi, MD · Contactrhsi1@hs.uci.edu · 657-579-4535
    • Roshan Patel, MD · Sub investigator
    • Pengbo Jiang, MD · Sub investigator
  • University of Minnesota
    Minneapolis, Minnesota 55454, United States
    Not yet recruiting
  • Columbia University Medical Center
    New York, New York 10032, United States
    Not yet recruiting
  • The Children's Hospital of Philadelphia
    Hatboro, Pennsylvania 19040, United States
    Recruiting
    • Rebecca D McCune, BS, MS · Contactmccuner@chop.edu · 267-909-6030
    • Brian Augelli, BS · Contactaugellib@chop.edu · 609-504-4908
    • Gregory E Tasian, MD, MSc, MSCE · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Sites
3 sites added, 1 site removed
Show 3 added (3 United States)
  • University of California, Irvine · Irvine, United States
  • Columbia University Medical Center · New York, United States
  • The Children's Hospital of Philadelphia · Hatboro, United States
Show 1 removed
  • The Children's Hospital of Philadelphia · Philadelphia, United States
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    3 sites added, 1 site removed
    Show 3 added (3 United States)
    • University of California, Irvine · Irvine, United States
    • Columbia University Medical Center · New York, United States
    • The Children's Hospital of Philadelphia · Hatboro, United States
    Show 1 removed
    • The Children's Hospital of Philadelphia · Philadelphia, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07718802
Collaborators
Patient-Centered Outcomes Research Institute
Responsible party
Sponsor
First posted
Jul 22, 2026
Start date
Aug 17, 2026
Primary completion
May 31, 2031 (estimated)
Completion
Oct 1, 2032 (estimated)
Last update
Oct 15, 2026

Study contacts

Rebecca D McCune, BS, MS
Contact
mccuner@chop.edu
267-909-6030
Brian J Augelli, BS
Contact
augellib@chop.edu
609-504-4908
Gregory E Tasian, MD, MSc, MSCE
principal investigator · Children's Hospital of Philadelphia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion